Study Shows Statins Could Be Effective against Small Cell Lung Cancer

“In a recent study, researchers at Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western), in collaboration with international colleagues, found that statins could be an effective therapeutic against metastatic small cell lung cancer (SCLC).

“The study of 876 late-stage SCLC patients, published today in the peer-reviewed scientific journal PLOS ONE, showed that statins, a class of drugs primarily used to lower cholesterol in patients at risk for heart disease, appeared to provide an increase in overall survival for those cancer patients who received them.

” ‘Small cell lung cancer is one of the most aggressive types of cancer, and yet in nearly three decades, no new classes of treatments have been adopted as new benchmarks for standard therapy,’ said Dr. Glen Weiss, M.D., M.B.A., Director of Clinical Research and Medical Oncologist at CTCA at Western in Goodyear, Ariz., and the study’s senior author. ‘Our study showed that statins appear to provide a statistically significant survival benefit among patients with metastatic SCLC.’ “


First 'Targeted' Treatment for Small Cell Lung Cancer Shows Promise

“Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has spread to other parts of the body (metastasised). Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only six percent. But today US researchers will present two novel findings with important implications for treatment at the 2015 European Cancer Congress.

“Dr M. Catherine Pietanza, MD, an Assistant Attending Physician at the Memorial Sloan Kettering Cancer Center, New York, USA, will report on results from a phase I trial of a novel agent, rovalpituzumab tesirine (Rova-T, or S16LD6.5), in 79 patients with SCLC who had progressed after first line (given when the disease is newly diagnosed) or second line therapy (given when the disease progresses or recurs).

” ‘While other cancers have multiple treatment options, there is only one agent approved in SCLC, and none available in the third line setting; the outlook for these patients is dismal,’ she will say. Third line therapy is given after first and second line treatments have failed to halt the progression of disease.”